Participants sought for studies Do you have cancer and feel depressed? Participate in a study on a new treatment for depression.
Depression among cancer patients is common, but there is currently no specific treatment for these patients. The CAPSI study is investigating a new treatment for cancer-related depression. The study is conducted in Region Stockholm, Uppsala, Örebro län, and Västra Götaland. The substance being investigated is psilocybin. One or two doses of psilocybin have in several smaller studies on depression, both with and without concurrent cancer, been shown to have a significant and long-lasting effect.
How does the study work?
A total of 100 patients with cancer and depression will be randomized to treatment on one occasion with 25 mg of psilocybin or, as a control, 1 mg of psilocybin. All participants will receive therapeutic support from a specially trained nurse before and after the treatment, for a total of five sessions. As part of the study, participants will also provide blood samples and undergo brain imaging. The study also includes a six-month follow-up period, with digital forms and video consultations.
When and where?
The study began in 2024 and is planned to continue until 2026. The following Swedish regions participate:
- Stockholm
- Uppsala
- Örebro län
- Västra Götaland
Who can participate in the study?
You may be eligible to participate if you:
- Have a cancer diagnosis for which you have received treatment or follow-up care within the past year
- Feel down or depressed
- Are between 20 and 80 years old
- Do not receive any other antidepressant treatment
- Do not have any psychotic disorder, bipolar disorder, or close relatives with these conditions
- Can read and understand Swedish
Apply to participate
Are you interested to know more? Click the link below for more information and to apply to participate. A study physician will then contact you within a few days for a follow-up interview.
Contact details
Evana López
Phd student and study doctorJohan Lundberg
Principal InvestigatorProcessing of personal data
Your personal data is processed for the purposes of this study in accordance with GDPR (General Data Protection Regulation). The legal entity responsible for processing of your personal data is Karolinska Institutet. The Data Protection Officer can be reached at dataskyddsombud@ki.se. The data will be analyzed on a group level, handled confidentially and it will be stored in a secure database at Karolinska Institutet. You can terminate your participation in the study at any time.